<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027934</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-14-10619</org_study_id>
    <nct_id>NCT03027934</nct_id>
  </id_info>
  <brief_title>A Single Center Study to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response</brief_title>
  <official_title>A Single Center, Randomized, Open Label, Crossover Study With Ticagrelor and Prasugrel to Evaluate Ticagrelor Mechanism of Action in Inhibiting Juvenile Platelet ADP Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CirQuest Labs, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CirQuest Labs, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to assess P2Y12 inhibition ex vivo in blood samples&#xD;
      obtained from diabetic subjects who will be administered one of the two P2Y12 antagonists in&#xD;
      a cross-over design.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study population difficult to recruit&#xD;
  </why_stopped>
  <start_date type="Anticipated">August 28, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aggregation Response</measure>
    <time_frame>23 hr Day 5</time_frame>
    <description>Comparison of aggregation response using ADP in subjects receiving prasurgrel versus ticagrelor</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reticulated Platelet Reactivity Index (PRI)</measure>
    <time_frame>23 hr Day 5</time_frame>
    <description>Comparison of PRI as measured by VASP in subjects receiving ticagrelor versus subjects receiving prasugrel</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor, 90mg twice daily</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Brilinta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasurgrel, 10mg once daily</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of informed consent prior to any study specific procedures&#xD;
&#xD;
          2. Male or female aged 18 to 70 years, inclusive.&#xD;
&#xD;
          3. Documented current medical history of diabetes controlled by either medication or diet&#xD;
             and/or exercise.&#xD;
&#xD;
          4. Women must have a negative urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating females, or females of child-bearing potential (i.e., those who&#xD;
             are not chemically or surgically sterilized or who are not post-menopause) or those&#xD;
             who are not willing to use a medically accepted method of contraception that is&#xD;
             considered reliable in the judgement of the investigator throughout the duration of&#xD;
             the study or females who have a positive pregnancy test at screening.&#xD;
&#xD;
          2. Weight of less than 135 lbs.&#xD;
&#xD;
          3. Currently prescribed and taking clopidogrel (generic or Plavix), ticagrelor (Brilinta)&#xD;
             or prasugrel (Effient) or have taken within the past 10 days.&#xD;
&#xD;
          4. Current medications:&#xD;
&#xD;
               1. PAR-1 antagonist (vorapaxar/Zontivity) or within the last month.&#xD;
&#xD;
               2. Phosphodiesterase inhibitors such as cilostazol (Pletal).&#xD;
&#xD;
               3. Glycoprotein IIb/IIIa inhibitors or within the last ten days (Integrilin,&#xD;
                  Aggrastat, ReoPro).&#xD;
&#xD;
               4. Adenosine reuptake inhibitors such as dipyridamole (Aggrenox, Persantine)&#xD;
&#xD;
               5. Coumadin.&#xD;
&#xD;
               6. Heparin including low molecular weight heparin.&#xD;
&#xD;
               7. Factor Xa inhibitors (e.g., enoxaparin, rivaroxaban, apixaban, and edoxaban).&#xD;
&#xD;
               8. Direct thrombin inhibitors (e.g., hirudin, bivalirudin, dabigatran.&#xD;
&#xD;
               9. Concomitant therapy with strong CYP3A inhibitors, such as atanazavir,&#xD;
                  clarithromycin, indinavir, itraconazole, ketoconazole, nefazadone, nelfinavir,&#xD;
                  ritonavir, saquinavir, telithromycin, and voriconizole,&#xD;
&#xD;
              10. Concomitant therapy with potent CYP3A inducers, such as rifampin, phenytoin,&#xD;
                  carbamazepine, and phenobarbital.&#xD;
&#xD;
          5. Increased bleeding risk including:&#xD;
&#xD;
               1. Recent (within 30 days) GI bleeding&#xD;
&#xD;
               2. Active pathological bleeding&#xD;
&#xD;
               3. Any history of intracranial, intraocular, retroperitoneal, or spinal bleeding&#xD;
&#xD;
               4. Prior history of transient ischemic attack or stroke&#xD;
&#xD;
               5. Recent (within 3 months) major trauma&#xD;
&#xD;
               6. Sustained uncontrolled hypertension (systolic blood pressure [SBP] &gt; 180mmHg or&#xD;
                  diastolic blood pressure [DBP] &gt; 100mmHg&#xD;
&#xD;
               7. History of hemorrhagic disorders that can increase the risk of bleeding (e.g.,&#xD;
                  hemophilia, von Willebrand's disease)&#xD;
&#xD;
               8. Patients that have used within 30 days of screening, any oral or parenteral&#xD;
                  anti-thrombotic agent.&#xD;
&#xD;
               9. Platelet count less than 100,000 mm3 or hemoglobin &lt; 10g/dL&#xD;
&#xD;
          6. Contraindication or other reason that ticagrelor or prasugrel should not be&#xD;
             administered (e.g., known hypersensitivity to medication or any medication component)&#xD;
&#xD;
          7. A history of alcohol and/or substance abuse that could interfere with conduct of the&#xD;
             trial.&#xD;
&#xD;
          8. Known active or recurrent hepatic disorder (including cirrhosis, hepatitis B and&#xD;
             hepatitis C, or confirmed (ALT/AST) levels &gt; 3 times ULN or total bilirubin &gt; 2 times&#xD;
             ULN at screening.&#xD;
&#xD;
          9. Scheduled for revascularization (e.g., PCI, CABG) during the study period.&#xD;
&#xD;
         10. Any Acute Coronary Syndrome (ACS) event within the past 6 months.&#xD;
&#xD;
         11. Participation in another investigational drug or device study within 30 days of&#xD;
             dosing.&#xD;
&#xD;
         12. Any acute or chronic unstable condition in the past 30 days or other condition which,&#xD;
             in the opinion of the investigator, may either put the subject at risk or influence&#xD;
             the result of the study (e.g., active cancer, risk for non-compliance, risk for lost&#xD;
             to follow-up).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jayaprakash Kotha</last_name>
    <role>Principal Investigator</role>
    <affiliation>CirQuest Labs</affiliation>
  </overall_official>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>July 13, 2020</last_update_submitted>
  <last_update_submitted_qc>July 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

